CD4 and neoplasm: Accumulating evidence suggests that both CD8+ and CD4+ T-cells in the tumor microenvironment (TME) play a crucial role in antitumor immune responses, but also that distinct populations may act as predictive biomarkers for immune checkpoint inhibitors [8, 9].